First biosimilar approved by FDA to treat common eye degeneration in elders
By
Alicia Lasek
Sep 21, 2021
The Food and Drug Administration has approved a less expensive copy of the blockbuster drug Lucentis for treating age-related (wet) macular degeneration and several other eye conditions.
Aggressive lobbying keeps seniors on Lucentis, prevents Medicare savings, USA TODAY article states
By
Tim Mullaney
Apr 28, 2014
Lobbying efforts have ensured that long-term care residents and other seniors are commonly prescribed the expensive drug Lucentis, even though the less costly drug Avastin has proven equally effective,...
CMS releases Medicare physician payment information, includes some nursing home affiliations
By
Tim Mullaney
Apr 10, 2014
Long-term care providers and residents now can glean insights into where their local doctors stack up nationally by referring to newly released data on Medicare physician payments. For the first time ever,...
Eye injections trim SNF use
By
Tim Mullaney
Mar 01, 2014
Injectable drugs ranibizumab (Lucentis) and bevacizumab (Avastin) help prevent nursing home admissions among those with age-related wet macular degeneration, according to findings in JAMA Ophthalmology.
Injectable drugs decrease risk of blindness-related nursing home admission by nearly 20%, researchers...
By
Tim Mullaney
Feb 03, 2014
Injectable drugs introduced in the last decade have proven effective in preserving vision and preventing nursing home admissions among those with age-related wet macular degeneration, according to recently...
Avastin more likely to cause blindness than Lucentis, study reports
By
McKnight's Staff
Jun 19, 2012
The cheaper of the two rival macular degeneration treatments could lead to blindness or other adverse events, new research determined.
FDA approves new macular degeneration treatment
Nov 22, 2011
The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision...
Macular degeneration treatment linked to blindness, FDA advisory says
Sep 06, 2011
Injections of the cancer drug Avastin, which is also a treatment for the wet form of age-related macular degeneration, has been linked to reports of blindness.
Government should be able to lower Medicare prescription drug prices, panel says
Jul 25, 2011
Further legislation is needed to empower the federal government to negotiate lower prescription drug prices in Medicare, a bipartisan panel concluded Thursday.
Cheaper macular degeneration treatment may be as effective
Apr 29, 2011
The cancer drug Avastin could be as effective as the more expensive Lucentis at improving the vision of seniors with macular degeneration, according to a report from The New York Times.